Most recently, Dr. Marantz served as the executive vice president and chief business officer at Krystal Biotech. Additionally, she currently serves on the board of Arcturus Therapeutics, according to a Nov. 9 Scholar Rock news release.
“I look forward to overseeing future clinical development, including the Phase 1 DRAGON proof-of-concept trial of SRK-181 in patients with advanced cancer, and progressing the Phase 3 SAPPHIRE trial of apitegromab for the treatment of SMA towards potential regulatory approval,” Dr. Marantz said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
